Skip to Content

You are here


Introduction and Goals

Although much less common than breast, lung, colon, or prostate cancers, tumors of the central nervous system are nonetheless an important public health problem, and one with which neurologists must have some familiarity. CNS tumors are in the differential for some of the most common chief complaints in neurology, including headache, seizure, and spells, and can result in acute, subacute, or chronically progressive focal deficits.

The goals of this elective rotation are for the PGY-3 or PGY-4 resident neurologist to develop an organized approach to the evaluation and treatment of patients with neurologic cancers with special emphasis on primary tumors. As time allows, residents may also be exposed to the treatment approach metastatic disease of the brain or spine. Residents will gain experience not only in medical oncology, but in radiation oncology, palliative care, neuroradiology, neuropathology, and interdisciplinary teamwork. Residents will also receive one-on-one didactic sessions with neuro-oncology faculty.

Objectives and Evaluation Matrix

As with all of the neurology rotations, the specific objectives are reflected in the entrustable professional activities and individual milestones listed below. These form the basis for the end-of-rotation evaluation. (Please see the section End-of-Rotation Evaluations above for the list of milestone abbreviations).


Work Hours

The estimated average number of work hours per week is ~ 50. There are no call responsibilities required during this rotation.

Suggested References

Nabors LB, Portnow J, Ammirati M, et al. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017;15(11):1331-1345.
Kruser TJ, Mehta MP, Robins HI. Pseudoprogression after glioma therapy: a comprehensive review. Expert Rev Neurother. 2013;13(4):389-403.
Tipping M, Eickhoff J, Ian Robins H. Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature. J Clin Neurosci. 2017;44:101-106.
Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
CONTINUUM: Lifelong Learning in Neurology. 23(6, Neuro-oncology):December 2017.
Latest revision: 07-16-2019